Link: The Heart Failure Society of America's clinical practice treatment guidelines, which cite the A-HeFT trial and direct the use of BiDil for certain groups.

African American Heart Failure Trial (A-HeFT) Peer-reviewed Scientific Publications

1.Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino D Jr, Ferdinand K, Taylor M, Adams, K, Sabolincki M, Worcel M, Cohn JN, for the African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-2057.

2.Taylor AL. The African American Heart Failure Trial: a clinical update. Am J Cardiol 2005;96[suppl]; 44i-48i.

3.Taylor AL, Wright JT Jr. Importance of race/ethnicity in clinical trials. Lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension and the Anithypertensive and Lipid-lowering Treatment to prevent Heart Attack Trial (ALLHAT). Circulation 2005;112:3654-3666.

4. Cohn JN. A-HeFT: old dog, new endothelial tricks. Tex Heart Onst J 2005;32:366-368.

5. Angus DC, Linde-Zwirble WT, Tam SW, Ghali JK, Sabolinski ML, Villagra VG, Winkelmayer WC, Worcel M for the African-American Heart Failure Trial (A-HeFT) Investigators. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation 2005; 112:3745-3753.

6. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Taylor AL, Cohn JN, Feldman AM, Worcel M. Aldosterone Synthase Promoter Polymorphism Predicts Outcome In African-Americans With Heart Failure: Results From The A-HeFT Trial. J Am Coll Cardiol 2006;48:1277-1282.

7.Taylor AL, Lindenfeld J, Ziesche S, Walsh MN, Mitchell JE, Adams K, Tam SW, Ofili E, Sabolinski ML, Worcel M, Cohn JN, for the A-HeFT Investigators. Outcomes By Gender in the African-American Heart Failure Trial. J Am Coll Cardiol 2006;48:2263-2267.

8.Anand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archambault WT, Adams KF, Olukotun AY, Worcel M, Cohn JN. Influence of Blood Pressure on the Effectiveness of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine in the African-American Heart Failure Trial . J Am Coll Cardiol 2007;49:32-39.

9.Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, Adams K, Olukotun AY, Ofili E, Tam SW, Sabolinski ML, Worcel M, Cohn JN, on behalf of the African-American Heart Failure Trial Investigators. Early and Sustained Benefit on Event-Free Survival and Heart Failure Hospitalization from Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine: Consistency Across Subgroups in the African-American Heart Failure Trial. Circulation 2007;115:1747-1753.

10.Cohn JN, Tam SW, Anand IS, Taylor AL, Sabolinski ML, Worcel M, for the A-HeFT Investigators. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces regression of left ventricular remodeling in a black population with heart failure: results from A-HeFT. J Card Fail 2007;13:331-339.

Manuscript in Press

1.Yancy CW, Ghali JK, Braman VM, Sabolinski ML, Worcel M, Archambault WT, Franciosa JA. Evidence for the Continued Safety and Tolerability of Fixed-Dose Isosorbide Dinitrate/Hydralazine in Patients with Chronic Heart Failure: the Extension to African-American Heart Failure Trial. Am J Cardiol 2007;in press.

Published abstracts:

1. Linde-Zwirble W, Tam SW, Sabolinski ML, Ghali J, Villagra VG, Winkelmayer WC, Angus DC. Fixed-dose combination of isosorbide dinitrate and hydralazine reduces heart failure hospitalizations, length of stay, and cost in A-HeFT (African-American Heart Failure Trial). J. Card Fail 2005;11[suppl]:S149.

2. Carson P, Ghali J, S. Tam SW, Worcel M. Fixed-dose combination of isosorbide dinitrate and hydralazine improves quality of life in African Americans with heart failure: results from A-HeFT. Heart Failure Society of American meeting, Boca Raton, FL, September 17-21, 2005. J. Card Fail 2005;11[suppl];S150.

3. Linde-Zwirble W, Tam SW, Worcel M, Sabolinski ML, Ghali J, Angus DC. In-trial economic evaluation of a fixed-dose combination of isosorbide dinitrate and hydralazine in blacks with heart failure: results from the African-American Heart Failure Trial (A-HeFT). J. Card Fail 2005;11[suppl]:S151.

4. McNamara DM, Tam SW, Sabolinski ML, Palmer E, Tobelman P, Janosko K, Feldman AM, Worcel M. The Genetic Risk Assessment in Heart Failure (GRAHF) sub-study of African-American Heart Failure Trial (A-HeFT): impact of genetic variation of NOS3. Heart Failure Society of American meeting, Boca Raton, FL, September 17-21, 2005. J. Card Fail 2005;11[suppl];S152.

5.Taylor AL, Ziesche S, Yancy YC, Carson P, Ferdinand K, Taylor K, Adams K, Olukotun A, Ofili E, Sabolinski M, Worcel M, Cohn JN. Early, Sustained Event-Free Survival from Fixed-Dose Isosorbide Dinitrate/Hydralazine: Increased Survival Is Consistent across Subgroups in Advanced Heart Failure. J Cardiac Failure 2005;11[suppl]:S149.

6.Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferrdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn J. African American Heart Failure Trial: Efficacy of a fixed dose combination of isosorbide dinitrate and hydralazine in heart failure. Circulation 2005;111:1726.

7. Cohn JN, Anand I, Taylor A, Tam, SW. Fixed-dose combination of isosorbide dinitrate and hydralazine inhibits left ventricular remodeling in well-treated severe heart failure in African Americans: A-HeFT. Circulation 2005;112:II-642.

8. Anand IS, Tam SW, Archambault WT, Olukotun AY, Adams KF, Worcel M, Sabolinski ML, Taylor AL, Cohn JN. Beneficial effects of isosorbide dinitrate-hydralazine on survival in heart failure is independent of its blood pressure lowering effect results from African American Heart Failure Trial. Circulation 2005;112:II-642.

9. Carson P, Ghali JK, Tam SW, Worcel M. Fixed-dose combination of isosorbide dinitrate and hydralazine improves quality of life in African Americans with heart failure: results from African-American Heart Failure Trial. Circulation 2005;112:II-643.

10. Tam SW, Linde-Zwirble W, Worcel M, Sabolinski ML, Ghali JK, Villagra VG, Winkelmayer WC, Angus DC. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for black patients with heart failure. Circulation 2005;112:II-643.

11. Cheng JW, Linde-Zwirble WT, Tam SW, Worcel M, Sabolinski ML, Ghali J, Angus DC. Cost-effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in blacks: results from the African-American Heart Failure Trial (A-HeFT). Abstract for American Society for Health-System Pharmacists (ASHP) Midyear Clinical Meeting, Dec 4-8, 2005, Las Vegas, NV.

12. Cohn JN, Anand I, Taylor A, Tam W. Fixed-dose combination of isosorbide dinitrate and hydralazine inhibits left ventricular remodeling in well-treated severe heart failure in African Americans: A-HeFT. J. Card Failure 2005;15:720.

13. McNamara DM, Tam SW, Sabolinski ML, Palmer E, Tobelman P, Janosko K, Feldman AM, Worcel M. Beta 1 adrenergic receptor Gly389Arg polymorphism and the impact of fixed-dose combination of isosorbide dinitrate/hydralazine in heart failure: results from the A-HeFT trial. JACC 2006;47 (Suppl):67A.

14. McNamara DM, Tam SW, Sabolinski ML, Palmer E, Tobelman P, Janosko K, Feldman AM, Worcel M. Aldosterone synthase promoter polymorphism modulates outcome in black patients with heart failure: results from the A-HeFT trial. JACC 2006;47 (Suppl):72A.

15. Taylor AL, Lindenfeld J, Ziesche S, Walsh MN, Mitchell J, Adams K, Worcel M, Sabolinski ML, Tam SW, Cohn JN for the A-HeFT Investigators. Outcomes by gender in the African-American Heart Failure Trial (A-HeFT). JACC 2006;47 (Suppl):84A.

16. Anand IS, Tam SW, Archambault WT, Olukotun AY, Adams KF, Worcel M, Sabolinski ML, Taylor AL, Cohn JN. Isosorbide dinitrate-hydralazine decreased blood pressure in patients with high but not low blood pressure and improved survival independent of baseline blood pressure in African-American Heart Failure Trial. JACC 2006;47 (Suppl):52A.

17. Cohn JN, Tam W, Anand IS, Worcel M, Sabolinski ML, Taylor AL. Clinical outcomes by baseline left ventricular ejection fraction in the African-American Heart Failure Trial. JACC 2006;47 (Suppl):83A.

18.Ghali JK, Taylor AL, Tam SW, Sabolinski ML, Worcel M, Cohn JN. Effect of Angiotensin Converting Enzyme Inhibitor or Beta-blocker Use on the Benefit of Fixed-Dose Combined Isosorbide Dinitrate/Hydralazine in the African-American Heart Failure Trial. J Card Fail 2006;12(6 Suppl):S71.

19. McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Hanley Yanez K, Janosko KM, Worcel M. GNB3 TT genotype predicts enhanced benefit of fixed-dose combination of isosorbide dinitrate and hydralazine in African Americans with Heart Failure: Results of the A-HeFT trial. J Card Fail 2006;12(6 Suppl):S80.

20. Carson P, Anand I, Ghali JK, Lindenfeld J, Miller A, O'Connor C, Tristani F, MD7, Braman VM, Worcel M, Sabolinski ML. Mode of Death in African American (AA) Heart Failure (HF) Population. J Card Fail 2006;12(6 Suppl):S75.

21.Yancy CW, Ghali JK, Braman VM, Sabolinski ML, Worcel M. Results of the extension to A-HeFT [X-A-HeFT] support the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine (ISDN/HYD). J Card Fail 2006;12(6 Suppl):S80.

22.Lindenfeld J, Taylor AL, Braman VM, Walsh MN, Cohn JN, and Sabolinski ML. Administration of fixed dose combination of isosorbide dinitrate(ISDN) and hydralazine(HYD) is associated with improved outcomes in post-menopausal women. J Card Fail 2006;12(6 Suppl):S86.

23.McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Hanley-Yanez K, Janosko KM, Worcel M. G protein beta 3 subunit (GNB3) genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of the A-HeFT trial. Ciriculation 2006;114:II-442.

24.Carson P, Anand I, Ghali JK, Lindenfeld J, Miller AB, Tristani F, Braman VM, Worcel M, Sabolinski ML. Impact of fixed-dose combination of isosorbide dinitrate and hydralazine on heart failure progression in an African American population: focus on mode of death and hospitalization. Circulation 2006;114:II-572.

25.Ghali JK, Taylor AL, Tam SW, Sabolinski ML, Worcel M, Cohn JN. Effect of angiotensin converting enzyme inhibitor or beta-blocker use on the benefit of fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial. Circulation 2006;114:II-572.

26.McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Hanley-Yanez K, Janosko KM, Worcel M. The ACE D allele and clinical outcomes in African Americans with heart failure. Circulation 2006;114:II-6710-II-672.

27.Sabolinski ML, Packer M, Tam SW, Worcel M, Cohn JN. The V-HeFT Paradox, Identical Doses of Different Formulations of Isosorbide Dinitrate and Hydralazine are not Bioequivalent and Neither is Bioequivalent to the Fixed-Dose Combination of ISDN/hydralazine Used in A-HeFT. JACC 2007;49 (Suppl A):64A.

28.Ghali JK, Tam SW, Taylor AL, Cohn JN, Worcel M, Sabolinski ML. Effect of Spironolactone Use on the Benefit of Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine in the African-American Heart Failure Trial. JACC 2007;49 (Suppl A):63A.

29.Ferdinand KC, Taylor AL, Tam SW, Sabolinski ML, Worcel M, Cohn JN. Effects of Standard Heart Failure Medications on Outcomes of Placebo-Treated Patients in the African-American Heart Failure Trial. JACC 2007;49 (Suppl A):87A.

30.Miller AB, Yancy CW, Sabolinski ML, Braman VM, Worcel M. Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Improves Outcomes in Heart Failure Patients With or Without Diabetes Mellitus: Results from African American Heart Failure Trial. JACC 2007;49 (Suppl A):44A